The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea
Open accessAbstract
Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by abdominal pain and alterations in stool form and/or frequency, leading to reduced quality of life. Pharmacologic agents currently approved by the US Food and Drug Administration for treatment of IBS with diarrhea (IBS-D) in adults are the nonsystemic antibiotic rifaximin, the mixed µ- and κ-opioid receptor agonist/δ-opioid antagonist eluxadoline, and the selective serotonin 5-HT 3 antagonist alosetron (the last of which is indicated only in women with severe IBS-D refractory to conventional therapy). Both eluxadoline and alosetron are administered as chronic daily therapies; rifaximin is given as a 2-week course of treatment with repeat courses administered as needed for symptom recurrence. Presumed mechanisms of action of rifaximin include modulation of the gut microbiota, anti-inflammatory activity, normalization of visceral hypersensitivity, and reduction in intestinal permeability. Eluxadoline targets opioid receptors in the gastrointestinal (GI) tract, resulting in decreased GI motility, fluid secretion, and visceral pain perception. Alosetron antagonizes serotonergic afferent neural signals and also slows GI motility. The efficacy and safety of these agents have been investigated in several rigorous clinical trials, and it has been demonstrated that they improve global and individual IBS symptoms. This review highlights the pivotal efficacy and safety data of the three pharmacologic agents currently indicated in the USA for the management of IBS-D in adults. Funding : Salix Pharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Camilleri, M., Northcutt, A. R., Kong, S., Dukes, G. E., McSorley, D., & Mangel, A. W. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02033-x · Cited by 556
Sperber, A. D., Dumitrascu, D., Fukudo, S., Gerson, C., Ghoshal, U. C., Gwee, K. A., Hungin, A. P. S., Kang, J.-Y., Minhu, C., Schmulson, M., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311240 · Cited by 554
Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact
Hungin, A. P. S., Chang, L., Locke, G. R., Dennis, E. H., & Barghout, V. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02463.x · Cited by 494
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Camilleri, Mayer, Drossman, Heath, Dukes, Mcsorley, Kong, Mangel, & Northcutt (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00610.x · Cited by 369
Eluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334
Lembo, A., Pimentel, M., Rao, S. S., Schoenfeld, P., Cash, B., Weinstock, L. B., Paterson, C., Bortey, E., & Forbes, W. P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.003 · Cited by 310
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Gut enterochromaffin cells drive visceral pain and anxiety
Bayrer, J. R., Castro, J., Venkataraman, A., Touhara, K. K., Rossen, N. D., Morrie, R. D., Maddern, J., Hendry, A., Braverman, K. N., Garcia-Caraballo, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05829-8 · Cited by 162
Shen, Y., Yu, J., Zhou, J., & Hu, G. (2024) · Journal of Medical Internet Research · doi:10.2196/59024 · Cited by 137
“Other examples include the approval of blinatumomab for pediatric acute lymphoblastic leukemia [88], ibrutinib for chronic lymphocytic leukemia [89], nusinersen for spinal muscular atrophy [90], and alosetron for irritable bowel syndrome in female patients [91].”
Liu, Y., Yu, X., Yu, L., Tian, F., Zhao, J., Zhang, H., Qian, L., Wang, Q., Xue, Z., Zhai, Q., et al. (2020) · Engineering · doi:10.1016/j.eng.2020.06.026 · Cited by 64
Research progress of colon-targeted oral hydrogel system based on natural polysaccharides
Wang, D., Wang, W., Wang, P., Wang, C., Niu, J., Liu, Y., & Chen, Y. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123222 · Cited by 53
Metadata
- Authors
- Brenner, D. M., & Sayuk, G. S.
- Affiliations
- Northwestern University (US)
- Washington University in St. Louis (US)
- Corresponding author
- Brenner, Darren M.
- Venue
- Advances in Therapy
- Published
- 2019-11-09
- Volume
- 37
- Issue
- 1
- Pages
- 83-96
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W2985697236
- Cited by
- 55
- References
- 34
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 13 · 2023: 8 · 2022: 7 · 2021: 11 · 2020: 6
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Advances in Therapy (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Salix Pharmaceuticals (Funding for technical editorial, medical writing support. Salix Pharmaceuticals also provided funding for this article to be published for open access.)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome with diarrhea, diarrhea-predominant irritable bowel syndrome, rifaximin, eluxadoline, alosetron, opioid agonists, 5-HT3 receptor antagonists, gut microbiota, visceral hypersensitivity, intestinal permeability, gastrointestinal motility, drug safety and efficacy, FDA-approved therapies
- MeSH terms
- Rifaximin, Adult, Carbolines, Diarrhea, Female, Gastrointestinal Agents, Humans, Imidazoles, Phenylalanine, Quality of Life, United States, United States Food and Drug Administration, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. https://app.cochat.ai/papers/10.1007/s12325-019-01116-z
- The paper
- Brenner, D. M., & Sayuk, G. S. (2020). Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Advances in Therapy. https://doi.org/10.1007/s12325-019-01116-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.